Yoshiaki Maruyama
Director, Office of Cellular and Tissue-based Products, Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Yoshiaki Maruyama is listed as Director, Office of Cellular and Tissue-based Products, Pharmaceuticals and Medical Devices Agency (PMDA), Japan. Yoshiaki is scheduled to speak at Advanced Therapies Week 2027 on 20 January 2027.
Compiled from published conference agendas; not yet confirmed by Yoshiaki. Is this you? Claim this profile.
About
I am currently a Director at the Office of Cellular and Tissue-based Products at the Pharmaceuticals and Medical Devices Agency (PMDA), Japan. In 2008, I joined PMDA as an officer in the Office of Compliance and Standards where I was also a secretariat for the Japanese Pharmacopoeia till 2012. I am in charge of a wide range of activities, from cell/gene therapy products, tissue-based product and biologics product approval reviews to post-market surveillance. I participated as Ministry of Health, Labour and Welfare (MHLW) and the PMDA topic leader for the development of ICH guidelines and Annexes on “Evaluation and Recommendation of Pharmacopoeial Texts for use in the ICH Regions (Q4B)”. Prior to joining PMDA, I was a research fellow at the University of Calgary, Canada from 2001 till 2005 and National Center of Neurology and Psychiatry (NCNP) Tokyo, Japan from 2005 till 2008.
Upcoming
Advanced Therapies Week 2027 19 January 2027 – 21 January 2027
- How do you plan and execute successful overseas IIT in the APAC and Australian regions? Speaker · 20 January 2027
- Keynote Regulatory Roundtable - perspectives on key areas of importance to the cell & gene therapy industry Speaker · 20 January 2027
- Plenary: Plotting a course to sustainable future success for the cell & gene therapy industry Speaker · 20 January 2027
Spoke alongside
People who have shared a session with Yoshiaki at events on B2DB.
- Samar Mohanty President & CSO · Nanoscope Therapeutics 2 shared sessions
- Steven Oh Director, Office of Cellular Therapy and Human Tissue, Office of Therapeutic Products, CBER · US Food & Drug Administration 2 shared sessions
- Sven Kili Partner · Saisei Ventures 1 shared session
- Cédric Cleyrat Executive Director, Head of Cell Therapy BioEngineering & Technology Innovation · Bristol Myers Squibb 1 shared session
- Gina Jiang Managing Director · Hong Kong Institute of Biotechnology 1 shared session
- Miguel Forte CEO, Kiji Therapeutics and Immediate Past President, International Society of Cell and Gene Therapy · Kiji Therapeutics 1 shared session
- Nelly Viseux VP Cell Therapies Development, Manufacturing Supply & Quality · Regeneron Pharmaceuticals 1 shared session
- Peter He Co-Founder & Chief Scientific Officer · OriCell Therapeutics 1 shared session